EA016811B1 - Полиморф в n-(2-аминофенил)-4-[n-(пиридин-3-ил)метоксикарбо-ниламинометил]бензамида (ms-275), способ его получения и применение для получения лекарственного средства для лечения заболеваний - Google Patents

Полиморф в n-(2-аминофенил)-4-[n-(пиридин-3-ил)метоксикарбо-ниламинометил]бензамида (ms-275), способ его получения и применение для получения лекарственного средства для лечения заболеваний Download PDF

Info

Publication number
EA016811B1
EA016811B1 EA201100354A EA201100354A EA016811B1 EA 016811 B1 EA016811 B1 EA 016811B1 EA 201100354 A EA201100354 A EA 201100354A EA 201100354 A EA201100354 A EA 201100354A EA 016811 B1 EA016811 B1 EA 016811B1
Authority
EA
Eurasian Patent Office
Prior art keywords
aminophenyl
methoxycarbonylaminomethyl
pyridin
benzamide
polymorph
Prior art date
Application number
EA201100354A
Other languages
English (en)
Russian (ru)
Other versions
EA201100354A1 (ru
Inventor
Маттиас Шнайдер
Михаэль Готтфрид
Йенс Гайслер
Габриеле Винтер
Original Assignee
Байер Фарма Акциенгезельшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41133825&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA016811(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Байер Фарма Акциенгезельшафт filed Critical Байер Фарма Акциенгезельшафт
Publication of EA201100354A1 publication Critical patent/EA201100354A1/ru
Publication of EA016811B1 publication Critical patent/EA016811B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EA201100354A 2008-08-29 2009-08-27 Полиморф в n-(2-аминофенил)-4-[n-(пиридин-3-ил)метоксикарбо-ниламинометил]бензамида (ms-275), способ его получения и применение для получения лекарственного средства для лечения заболеваний EA016811B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9304608P 2008-08-29 2008-08-29
EP08163274 2008-08-29
PCT/EP2009/006381 WO2010022988A1 (en) 2008-08-29 2009-08-27 N-(2-aminophenyl)-4-[n-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (ms-275)polymorph b

Publications (2)

Publication Number Publication Date
EA201100354A1 EA201100354A1 (ru) 2011-10-31
EA016811B1 true EA016811B1 (ru) 2012-07-30

Family

ID=41133825

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201100354A EA016811B1 (ru) 2008-08-29 2009-08-27 Полиморф в n-(2-аминофенил)-4-[n-(пиридин-3-ил)метоксикарбо-ниламинометил]бензамида (ms-275), способ его получения и применение для получения лекарственного средства для лечения заболеваний

Country Status (35)

Country Link
US (2) US7973166B2 (enExample)
EP (1) EP2350005B1 (enExample)
JP (1) JP4921616B2 (enExample)
KR (1) KR101073760B1 (enExample)
CN (1) CN102137846B (enExample)
AR (1) AR073226A1 (enExample)
AT (1) ATE538094T1 (enExample)
AU (1) AU2009286982C1 (enExample)
BR (1) BRPI0918580B8 (enExample)
CA (1) CA2735294C (enExample)
CO (1) CO6351736A2 (enExample)
CR (2) CR20110107A (enExample)
CY (1) CY1112645T1 (enExample)
DK (1) DK2350005T3 (enExample)
DO (1) DOP2011000064A (enExample)
EA (1) EA016811B1 (enExample)
EC (1) ECSP11010849A (enExample)
ES (1) ES2378640T3 (enExample)
HN (1) HN2011000609A (enExample)
HR (1) HRP20120183T8 (enExample)
IL (1) IL211276A (enExample)
MA (1) MA32610B1 (enExample)
MX (1) MX2011002248A (enExample)
MY (1) MY149058A (enExample)
NZ (1) NZ591387A (enExample)
PE (2) PE20141062A1 (enExample)
PL (1) PL2350005T3 (enExample)
PT (1) PT2350005E (enExample)
RS (1) RS52164B (enExample)
SI (1) SI2350005T1 (enExample)
SM (1) SMT201200026B (enExample)
SV (1) SV2011003846A (enExample)
TW (1) TWI427062B (enExample)
WO (1) WO2010022988A1 (enExample)
ZA (1) ZA201102285B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20120183T8 (en) 2008-08-29 2012-11-30 Bayer Pharma Aktiengesellschaft N-(2-aminophenyl)-4-[n-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (ms-275)polymorph b
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
FR2977492B1 (fr) * 2011-07-04 2013-07-05 Servier Lab Nouvelle association entre le n-hydroxy-4-{2-[3-(n,n-dimethylaminomethyl) benzofuran-2-ylcarbonylamino]ethoxy}benzamide et le folfox
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
WO2016077451A1 (en) 2014-11-12 2016-05-19 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
EP3168210A1 (en) 2015-11-13 2017-05-17 Sandoz Ag Crystalline forms of entinostat
WO2017216761A1 (en) * 2016-06-17 2017-12-21 Dr. Reddy's Laboratories Limited Solid forms of entinostat
US11208382B2 (en) 2017-07-28 2021-12-28 Hangzhou Solipharma Co., Ltd. Entinostat-containing compound, crystal form of compound thereof, and preparation method therefor and pharmaceutical composition thereof
US20240239748A1 (en) 2021-05-10 2024-07-18 Macfarlan Smith Limited Novel forms of entinostat

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0847992A1 (en) * 1996-09-30 1998-06-17 Mitsui Chemicals, Inc. Benzamide derivatives, useful as cell differentiation inducers
JP2001131130A (ja) * 1999-11-09 2001-05-15 Mitsui Chemicals Inc モノアシルフェニレンジアミン誘導体の精製法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3354090B2 (ja) * 1996-09-30 2002-12-09 シエーリング アクチエンゲゼルシャフト 分化誘導剤
JP4030683B2 (ja) * 1998-07-24 2008-01-09 三井化学株式会社 ベンズアミド誘導体の合成法
US6320078B1 (en) * 1998-07-24 2001-11-20 Mitsui Chemicals, Inc. Method of producing benzamide derivatives
JP2001064177A (ja) * 1999-08-16 2001-03-13 Schering Ag ベンズアミド誘導体を有効成分とする製剤
PE20050206A1 (es) * 2003-05-26 2005-03-26 Schering Ag Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
HRP20120183T8 (en) 2008-08-29 2012-11-30 Bayer Pharma Aktiengesellschaft N-(2-aminophenyl)-4-[n-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (ms-275)polymorph b

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0847992A1 (en) * 1996-09-30 1998-06-17 Mitsui Chemicals, Inc. Benzamide derivatives, useful as cell differentiation inducers
JP2001131130A (ja) * 1999-11-09 2001-05-15 Mitsui Chemicals Inc モノアシルフェニレンジアミン誘導体の精製法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CAIRA M.R.: "CRYSTALLINE POLYMORPHISM OF ORGANIC COMPOUNDS", TOPICS IN CURRENT CHEMISTRY, SPRINGER, BERLIN, DE, vol. 198, 1 January 1998 (1998-01-01), pages 163-208, XP001156954, page 165-page 166 *

Also Published As

Publication number Publication date
PL2350005T3 (pl) 2012-05-31
BRPI0918580A8 (pt) 2017-07-11
ECSP11010849A (es) 2011-03-31
MY149058A (en) 2013-07-15
PE20110677A1 (es) 2011-09-16
US7973166B2 (en) 2011-07-05
AU2009286982C1 (en) 2012-04-26
TW201014820A (en) 2010-04-16
SI2350005T1 (sl) 2012-03-30
NZ591387A (en) 2012-03-30
JP2012500819A (ja) 2012-01-12
PT2350005E (pt) 2012-03-12
HN2011000609A (es) 2014-09-29
CA2735294A1 (en) 2010-03-04
CN102137846B (zh) 2014-04-23
EP2350005A1 (en) 2011-08-03
CY1112645T1 (el) 2016-02-10
AU2009286982B2 (en) 2011-06-23
ATE538094T1 (de) 2012-01-15
DK2350005T3 (da) 2012-03-19
BRPI0918580A2 (pt) 2015-12-01
EA201100354A1 (ru) 2011-10-31
BRPI0918580B8 (pt) 2021-05-25
TWI427062B (zh) 2014-02-21
RS52164B (sr) 2012-08-31
CA2735294C (en) 2013-10-15
KR101073760B1 (ko) 2011-10-13
CN102137846A (zh) 2011-07-27
HRP20120183T8 (en) 2012-11-30
ES2378640T3 (es) 2012-04-16
USRE45499E1 (en) 2015-04-28
CO6351736A2 (es) 2011-12-20
JP4921616B2 (ja) 2012-04-25
IL211276A (en) 2014-07-31
CR20160465A (es) 2016-12-06
EP2350005B1 (en) 2011-12-21
MA32610B1 (fr) 2011-09-01
US20100056585A1 (en) 2010-03-04
SMT201200026B (it) 2012-07-10
HRP20120183T1 (hr) 2012-03-31
MX2011002248A (es) 2011-03-29
CR20110107A (es) 2011-04-28
DOP2011000064A (es) 2011-03-31
IL211276A0 (en) 2011-04-28
WO2010022988A1 (en) 2010-03-04
SV2011003846A (es) 2011-07-27
HK1160107A1 (en) 2012-08-10
AR073226A1 (es) 2010-10-20
BRPI0918580B1 (pt) 2020-11-24
PE20141062A1 (es) 2014-09-19
AU2009286982A1 (en) 2010-03-04
ZA201102285B (en) 2011-12-28
KR20110038187A (ko) 2011-04-13

Similar Documents

Publication Publication Date Title
EA016811B1 (ru) Полиморф в n-(2-аминофенил)-4-[n-(пиридин-3-ил)метоксикарбо-ниламинометил]бензамида (ms-275), способ его получения и применение для получения лекарственного средства для лечения заболеваний
EA023646B1 (ru) Замещённые соли 2,3-дигидроимидазо[1,2-c]хиназолина
TWI469980B (zh) 製備（＋）－１，４－二氫－７－〔（３ｓ，４ｓ）－３－甲氧基－４－（甲胺基）－１－吡咯啶基〕－４－酮基－１－（２－噻唑基）－１，８－萘啶－３－羧酸之方法
CA3122576C (en) CRYSTALLINE FORMS OF THE NRTTI COMPOUND OF 4'-ETHYNYL-2-FLUORO-2'-DESOXYADENOSINE
CN110357858A (zh) 具有穿过血脑屏障能力的5取代二氟哌啶化合物
EP3130588B1 (en) Polysubstituted pyridine compound, preparation method, use and pharmaceutical composition
CN118290384B (zh) 大豆苷元与哌嗪共晶物及制备方法和其组合物与用途
CN113993842B (zh) 琥珀酸酯前药、包含琥珀酸酯前药的组合物及其用途
JP6523259B2 (ja) イコチニブリン酸塩の新規な多形及びその使用
CZ308865B6 (cs) Mesylátová sůl para-topolinu, přípravky ji obsahující, a její použití
CN102276625B (zh) 噻二唑衍生物
EP3750894A1 (en) Urea-substituted aromatic ring-linked dioxazoline compound, preparation method therefor, and uses thereof
CN115477647A (zh) 小檗碱富马酸盐晶型及其制备方法和其组合物与应用
HK1160107B (en) N-(2-aminophenyl)-4-[n-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (ms-275)polymorph b
TW202241846A (zh) 具有ｅｐ拮抗活性之化合物的鹽、溶劑合物及結晶
CN119841776A (zh) 酪氨酸激酶抑制剂和其用途
TW201512203A (zh) 埃克替尼馬來酸鹽的晶型及其用途

Legal Events

Date Code Title Description
RH4A Grant of a duplicate of a eurasian patent
PC4A Registration of transfer of a eurasian patent by assignment
QB4A Registration of a licence in a contracting state
QB4A Registration of a licence in a contracting state
QB4A Registration of a licence in a contracting state
QB4A Registration of a licence in a contracting state
QC4A Termination of a registered licence in a contracting state
QZ4A Registered corrections and amendments in a licence
QB4A Registration of a licence in a contracting state
QB4A Registration of a licence in a contracting state
QB4A Registration of a licence in a contracting state